Joined February 2012
- Tweets 4,520
- Following 760
- Followers 373
- Likes 410
22 Photos and videos
Thomas Pierret 🫁 retweeted
Jun 14
AUDIO 🎧 Le thymus, un organe clé insoupçonné du système immunitaire l.franceinfo.fr/Ads
4
12
17
10,668
Thomas Pierret 🫁 retweeted
Jun 13
🚨While @SpaceX goes IPO and the world's glued to @FIFAWorldCup ⚽🚀an interesting paper popped up for your Friday read @NatureMedicine
👉Frontier general LLMs (GPT-5.2, Gemini 3.1 Pro, Claude Opus 4.6) outperformed specialized clinical AI tools (OpenEvidence, UpToDate Expert AI) on medical knowledge, clinician alignment 1,800 blinded physician annotations on real clinical queries🤯
👉This result was unexpected 🤯🤔 👉"Specialized" ≠ "Better" @OncoAlert
nature.com/articles/s41591-0…
4
23
49
10,299
Thomas Pierret 🫁 retweeted
Jun 10
🫁 ICI Rechallenge in ES-SCLC.
In a real-world study of 151 patients progressing after first-line chemoimmunotherapy, ICI rechallenge improved ORR (26% vs 11.8%), PFS2 (3.98 vs 2.43 months), and OS (9.43 vs 6.23 months), with low rates of severe irAEs (2%).
Prospective validation is needed, but these findings support reconsidering immunotherapy in selected patients with relapsed ES-SCLC.
📖 Lung Cancer
DOI 👉🏻 doi.org/10.1016/j.lungcan.20…
#CánCare #SCLC #lcsm #Immunotherapy #ThoracicOncology
1
12
46
5,686
Thomas Pierret 🫁 retweeted
What does chemo add to immunotherapy in pts w/ PD-L1-high NSCLC?
In our meta-analysis of 24 trials w/ reconstructed individual patient data, we observed a meaningful improvement in both median PFS (11.3 vs 6.8 months, HR 0.74) and OS (29.2 vs 19.8 months, HR 0.67) w/ chemo-ICI.
Jun 4
A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #NSCLC with high #PDL1, though with greater toxicity. ja.ma/4o4nvaH
4
31
96
16,329
Thomas Pierret 🫁 retweeted
☢️ Concurrent thoracic radiotherapy chemotherapy durvalumab phase III trial in stage IV SCLC stopped early due to excess of deaths in the radiotherapy arm.
Not improvement in ORR, PFS, or OS but added toxicity to standard CASPIAN.
A definitively NOT TO DO. #ASCO26 #LCSM
1
14
23
3,566
Thomas Pierret 🫁 retweeted
Dr. @drshieldsmd gives a great discussion on SCLC at #ASCO26. Tarlatamab update shows the drug raises the bar but points out importance of ICANS awareness. Is it higher in its with brain metastases?
2
28
80
5,168
Thomas Pierret 🫁 retweeted
Tarlatamab continues to impress the oncology community with the CNS activity in relapsed ES-SCLC presented today.
🧠 Controlling not only previously treated brain metastases at baseline but also preventing them from appearing, while maintaining a better tox profile than chemotherapy, with the exception of disgeusia 👅 and increased ICANS
#ASCO26 #LCSM
1
9
13
770
Thomas Pierret 🫁 retweeted
Jun 1
#ASCO26
One of the most clinically relevant SCLC updates of the meeting.
In DeLLphi-304, tarlatamab not only improved OS versus chemotherapy, but also showed meaningful intracranial activity:
• CNS progression/death HR 0.54 overall
• HR 0.40 in patients with brain metastases
• CNS CR 15% vs 5%
For a disease where brain progression remains a major challenge, these results matter
@OncoAlert @StephenVLiu @christine_lovly @GlopesMd @RManochakian @OncoReporte @MedwatchKate @weoncologists
13
14
688
Thomas Pierret 🫁 retweeted
SYS6043 B7-H3 ADC ; B7-H3 expresssion levels didn’t correlate with response in lung. #ASCO26
1
5
6
610
Thomas Pierret 🫁 retweeted
Jun 1
#ASCO2026 | LORIN Phase II
Neoadjuvant lorlatinib in stage III ALK NSCLC delivered impressive results:
pCR 47%,MPR 81%,ORR 84%, 75% surgical conversion in initially unresectable disease
Small, single-arm study? Absolutely. Randomized confirmation needed? Of course.Practice changing? Debatable.
But if I see a stage III ALK patient tomorrow, these data would be very hard for me to ignore. I probably wouldn’t hesitate to discuss a neoadjuvant ALK-directed approach at the MDT.
#LungCancer #NSCLC #ALK #Lorlatinib #PrecisionOncology #ASCO26
16
38
7,345
Thomas Pierret 🫁 retweeted
🆙 #ASCO26 #LCSM Oral
🔥LORIN: Neoadj Lorlatinib in Stage III ALK NSCLC
✅ORR 83.7%, pCR 46.9%, MPR 81.3%
✅75% unresectable → conversion surgery
✅1y EFS 97.1%
🎙️Dr. Chao Zhang
🔢8002
☑️NCT05740943
🔗 asco.org/abstracts-presentat…
@OncoAlert @Larvol @ASCO @IASLC @ALKPositiveinc
7
14
3,078
Thomas Pierret 🫁 retweeted
🆙 #ASCO26 #LCSM Rapid Oral
🔥AEGEAN: TME Transcriptomic Analysis
✅3 clusters: C1 desert, C2 suppressed, C3 activated
✅Neoadj Durlva: C1 at surg 17.9% vs 47.2% (PBO); C3 EFS HR 0.16
🎙️Dr. John V. Heymach
🔢8015
☑️NCT03800134
🔗 asco.org/abstracts-presentat…
@OncoAlert @Larvol @ASCO @IASLC
11
15
1,382
Thomas Pierret 🫁 retweeted
🆙 #ASCO26 #LCSM Rapid Oral
🔥Tumor-Naïve Multimodal MRD after Resection
✅Landmark MRD : rec HR 9.72
✅Longitudinal MRD : HR 16.64; lead time 264 days
✅Robust in all stages incl. stage I
🎙️Dr. Di Lu
🔢8016
🔗 asco.org/abstracts-presentat…
@OncoAlert @Larvol @ASCO @IASLC #Liquidbiopsy
6
8
746
Thomas Pierret 🫁 retweeted
🆙 #ASCO26 #LCSM Rapid Oral
🔥TRACERx: Ultrasensitive Sub-10 PPM ctDNA MRDNSCLC
✅Post-op <10 PPM: RFS HR 3.49, OS HR 2.58 vs undetected
✅ctDNA preceded imag in 120 pts
🎙️Dr. Jonathan Wan
🔢8017
🔗 asco.org/abstracts-presentat…
@OncoAlert @Larvol @ASCO @IASLC #Liquidbiopsy
8
13
2,702
Thomas Pierret 🫁 retweeted
🆙 #ASCO26 #LCSM Oral
🔥ALCHEMIST (EA5142): Adj Nivo after Surgery Chemo in Resected NSCLC
✅DFS HR 0.97 (95%CI 0.81-1.17)
✅PD-L1 ≥50%: DFS HR 0.86 (95%CI 0.59-1.25)
🎙️ @ChaftJamie
🔢8000
☑️NCT02595944
🔗 asco.org/abstracts-presentat…
@OncoAlert @Larvol @ASCO @IASLC
6
15
6,612
Thomas Pierret 🫁 retweeted
May 24
TAXIO/IFCT-2203 (Abs 8091): paclitaxel/carbo/durva in 1L ES-SCLC.
👉ORR 82.4%,
👉12-mo OS 57.4%,
👉mOS 14.5 mo,
👉mPFS 4.6 mo.
Safety: grade 3-5 TRAEs 48.5%; 2 treatment-related sepsis deaths.
Bottom line: active convenient one-day regimen, but toxicity is real and PFS does not scream “better than EP/IO.” would be nice especially for inpatients induction.
1
5
3
244
Thomas Pierret 🫁 retweeted
May 31
LIBRETTO 432 @NEJM after #ASCO26: phase III adjuvant selpercatinib vs placebo x 3y in pts w/ resected RET NSCLC (n=151). 2y EFS rate 92% vs 61% (HR 0.17). Most common AEs were LFT elevation. Fits established paradigm and sets a new standard of care.
nejm.org/doi/full/10.1056/NE…
12
28
1,374
Thomas Pierret 🫁 retweeted
May 30
Pumitamig, a novel PD-L1/VEGF-targeted bispecific antibody, shows encouraging efficacy in combination with chemotherapy as a 1st line treatment for NSCLC, even when PD-L1 expression is low. Responses appear to be durable, but longer term follow-up will be informative. #ASCO2026
5
13
931
Thomas Pierret 🫁 retweeted
#ASCO2026
PD-(L)1 × VEGF-A bispecifics are generating early excitement in NSCLC.
✅ Responses across squamous and non-squamous histologies
✅ Activity across PD-L1 subgroups
✅ Limited high-grade bleeding toxicity
Early data only—but a potentially important new direction in frontline immunotherapy.@OncoAlert @ozdogan_md
5
4
731
Thomas Pierret 🫁 retweeted
May 30
1stL in KRASG12Cmut NSCLC will be crowded and complex. Elisrasib, another KRASG12Coff inh, reported activityn in 1stL alone and combo with pembro. Next future: how to decide intensification? Based on PDL1, comut, brain met status🤯.Will not be easy!! To icity is a concern #ASCO26
37
71
3,672